COMPANY

RegCell

Keywords: cell therapy immunology autoimmune diseases

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Undisclosed round · $66M · announced Sep 15, 2026 Company release ↗
Source quote
- Sep 15, 2026 · Company release ↗
  “RegCell Secures $66 Million of Additional Funding to Bring Nobel-Winning Immune Tolerance Science to the Clinic”
- Sep 17, 2026 · Company release ↗
  “Regcell Inc. has raised $66 million in new financing and Japanese government support to move its Nobel-linked regulatory T-cell (Treg) platform toward the clinic”
Raise Seed · amount not disclosed · announced Mar 18, 2025 Company release ↗
Source quote
- Mar 18, 2025 · Company release ↗
  “— RegCell, Inc., a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the natural biology of regulatory T-cells (Tregs), today announced the closing of an oversubscribed seed”

Raises announced in these releases: $66M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Sep 15, 2026 Raise Private equity round: $66M (total, as published), announced Sep 15, 2026. Source: company's own press page. source ↗
Sep 15, 2026 Raise Undisclosed round · $66M source ↗
Mar 18, 2025 Raise Seed · amount not disclosed source ↗

Raised: $66.0M. Last 2 years.

Sep 15, 2026 Private equity round: $66M (total, as published), announced Sep 15, 2026. Source: company's own press page. source ↗